Skip to main content

Table 1 Demographic data for individuals with samples at a median of 4.6 years (Q1 to Q3: 2.0 to 9.7) before the onset of symptoms of rheumatoid arthritis (RA) (pre-symptomatic individuals) at diagnosis and controls

From: Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis

 

Pre-symptomatic individuals

RA

Controls a

(n = 370)

(n = 203)

(n = 585)

Females (%)

81

77

71

Median age, years

49.9

56.5

50.3

(Q1-Q3) g

(30.6–58.8)

(48.7–63.7)

(40.2–60.1)

Ever-smoker (%)

230/348 (66.1)***

136/200 (68)***

254/552 (46.0)

HLA-DR SEb, n (%)

240/366 (65.6) ***

129/204 (63.2) ***

229/585 (39.1)

anti-CCP2 absc, % (95% CI)

34.9 (30.2–39.9)***

74.5 (68.0–80.0)***d

2.4 (1.4–4.0)

anti-CEP-1/Eno5-21 abs, % (95% CI)

28.9 (24.5–33.7)***

67.3 (60.5–73.5)***e

6.1 (4.4–8.4)f

anti-citC1359-369 abs, % (95% CI)

13.1 (10–17.1)***

32.2 (26.1–39.0)***e

4.4 (3.0–6.4)f

anti-Fibα563-583 abs, % (95% CI)

10.8 (8–14.4)***

34.2 (27.9–41.0)***e

5.2 (3.6–7.4)f

anti-Fibα580-600 abs, % (95% CI)

8.7 (6.2–12.1)

14.1 (9.9–19.7)***e

6.1 (4.4–8.4)f

anti-Fibß36-52 abs, % (95% CI)

29.7 (25.3–34.6)***

64.8 (58.0–71.1)***e

6.6 (4.9–9.0)f

anti-Fibß62-81a (72) abs, % (95% CI)

11.6 (8.7–15.3)***

14.6 (10.3–20.2)***e

3.1 (2.0–5.0)f

anti-Fibß62-81b (74) abs, % (95% CI)

15.9 (12.5–20.1)***

34.2 (27.9–41.0)***e

1.7 (0.9–3.2)f

anti-CCP-1/Fil307-324 abs, % (95% CI)

26.2 (22–30.9)***

46.2 (39.4–53.2)***e

3.0 (1.8–4.7)f

anti-Vim60-75 abs, % (95% CI)

13.0 (9.9–16.8)***

29.1 (23.3–35.8)***e

5.4 (3.8–7.6)f

anti-Vim2-17 abs, % (95% CI)

7.0 (4.8–10.2)*

11.1 (7.4–16.3)***e

3.8 (2.5–5.8)f

  1. *P <0.05, ***P <0.001 pre-symptomatic individuals or RA patients, respectively compared with controls.
  2. aThe sensitivity and specificity calculations are based on ROC curves performed originally on the RA cases (n = 200/199) and controls (n = 1,307) [5]. bHLA-DR SE = shared epitope defined as 0101/0401/0404/0405/0408/. cabs = antibodies. davailable number of samples analysed = 200. en = 199. fn = 574. g (Q1-Q3)=first quartile to third quartile.